Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
AssigneeInnate Pharma
InventorsAndrea Velardi, Francois Romagne
Life of this patent
Estimating the term…
Abstract
The present invention relates, generally, to methods and compositions for increasing the efficiency of therapeutic antibodies. Their efficiency is enhanced through the increase of the ADCC mechanism. More particularly, the invention relates to the use of a therapeutic antibody in combination with compounds that block an inhibitory receptor or stimulate an activating receptor of an NK cell in order to enhance the efficiency of the treatment with therapeutic antibodies in human subjects.
Claims24
A method of inhibiting the activity of an inhibitory receptor expressed on a NK cell comprising:
- (a) administering to a subject an antibody or an antigen binding fragment thereof that binds to and inhibits the activity of the KIR2DL1, KIR2DL2/3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR3DL1, KIR3DL2, KIR3DL3, LILRB1, NKG2A, NKG2C, NKG2E or LILRB5 receptor on a NK cell;
- and,
- (b) administering to said subject a therapeutic antibody that binds CD16 via the Fc portion of said therapeutic antibody.
A method of increasing the efficiency of a treatment involving the administration of a therapeutic antibody that can be bound by CD16 in a subject, said method comprising the administration, to a subject, of a therapeutic antibody that can be bound by CD16 via the Fc portion of said therapeutic antibody and administering to said subject prior to, simultaneously with, or following the administration of said therapeutic antibody, a therapeutically-effective amount of an antibody that binds to and blocks an inhibitory receptor of an NK cell.
Dependencies are inferred from the claim text.